Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
A6NNB3
UPID:
IFM5_HUMAN
Alternative names:
Bone-restricted interferon-induced transmembrane protein-like protein; Dispanin subfamily A member 1
Alternative UPACC:
A6NNB3
Background:
Interferon-induced transmembrane protein 5, also known as Bone-restricted interferon-induced transmembrane protein-like protein and Dispanin subfamily A member 1, plays a crucial role in bone mineralization. This protein's involvement in the biological process is essential for maintaining bone strength and integrity.
Therapeutic significance:
Osteogenesis imperfecta 5, a condition marked by bone fragility and susceptibility to fractures, is directly associated with mutations in the gene encoding this protein. Understanding the role of Interferon-induced transmembrane protein 5 could open doors to potential therapeutic strategies for managing and treating this debilitating disease.